This poster describes the qualification of microneutralisation (MN) assays for human metapneumovirus (hMPV) and human parainfluenza virus type 3 (HPIV‑3), developed to support clinical vaccine evaluation. The assays were designed to measure functional neutralising antibodies and were qualified across key performance parameters, including specificity, accuracy, precision, linearity, and assay range.
Robust virus batch release procedures were implemented to ensure consistency between virus stocks and long‑term assay reliability. The qualified MN assays demonstrated suitable performance to support immunogenicity assessment in Phase I and Phase II clinical studies and are applicable to the evaluation of vaccines targeting respiratory viruses with high unmet medical need. The work was presented by Aloys Tijsma at World Vaccine Congress Europe 2025 in Amsterdam.
